Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B co-infection.
Chronic hepatitis B virus (HBV) infection increases the risk of liver injury in patients undergoing treatment for tuberculosis (TB). It is uncertain whether antiviral treatment for HBV at the time of TB diagnosis would reduce the risk of liver injury. Among 3698 patients with TB-HBV co-infection, 488 (13.2%) were "patients on antiviral therapy". Among the remaining 3210 patients, 446 (13.9%) started antiviral therapy after diagnosis of TB. Adjusted for propensity score, "patients on antiviral therapy" had a lower risk of hospitalization due to drug-induced liver injury, compared with those not on treatment (adjusted hazard ratio 0.44, 95% CI 0.26-0.72). Compared with "patients started antiviral therapy after diagnosis of TB", "patients on antiviral therapy" also had lower risk of hospitalization due to drug-induced liver injury, and a lower risk of liver-related mortality. Our study showed that antiviral treatment for HBV given at the time of TB diagnosis reduced the risk of liver injury in TB-HBV co-infected patients.